专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08765197B2 Extract of herbal and composition containing the same 有权
标题翻译：提取物含有相同的草药和成分
公开(公告)号：US08765197B2
公开(公告)日：2014-07-01
申请号：US12224327
申请日：2007-02-27
申请人： Mi Won Son , Sang Jin Choi , Chong Hwan Cho , Nam Joon Baek , Tae Ho Lee , Jae Keol Rhee , Soon Hoe Kim , Moo Hi Yoo , Mi Rim Jin , Jin Pub Son
发明人： Mi Won Son , Sang Jin Choi , Chong Hwan Cho , Nam Joon Baek , Tae Ho Lee , Jae Keol Rhee , Soon Hoe Kim , Moo Hi Yoo , Mi Rim Jin , Jin Pub Son
IPC分类号： A61K36/00 , A61K36/31
CPC分类号： A23L2/52 , A23L33/105 , A61K36/31 , A61K36/39 , A61K36/505 , A61K36/56 , A61K2300/00
摘要： The present invention relates to herbal extracts of Sinapis Semen, Corydalis Tuber, Pharbitidis Seed, and Strychni Ignatii Semen, and a composition containing the same for treating and preventing gastrointestinal motility disorder. The extracts of the present invention have a remarkable effect of promoting gastrointestinal motility through HT3 receptor antagonism and/or HT4 receptor antagonism.
摘要翻译：本发明涉及Sinapis Semen，Corydalis Tuber，Pharbitidis Seed和Strychni Ignatii Semen的草药提取物，以及含有它们的用于治疗和预防胃肠蠕动障碍的组合物。本发明的提取物具有通过HT3受体拮抗作用和/或HT4受体拮抗作用促进胃肠蠕动的显着效果。

2. 发明授权

US08203011B2 3′,4′,5-trimethoxy flavone derivatives as stimulant of mucus secretion, method for the same, and pharmaceutical composition comprising the same 有权
标题翻译： 3'，4'，5-三甲氧基黄酮衍生物作为粘液分泌的刺激剂，其方法和含有该组合物的药物组合物
公开(公告)号：US08203011B2
公开(公告)日：2012-06-19
申请号：US12451902
申请日：2008-06-02
申请人： Seul-Min Choi , Kyung-Koo Kang , Dong-Sung Kim , Jeong-Hoon Kim , Byoung-Ok Ahn , Moo-Hi Yoo , Mi-Jeong Seo , Ju-Mi Kim , Yong-Duck Kim , Sun-Woo Jang , Yong-Sung Shon
发明人： Seul-Min Choi , Kyung-Koo Kang , Dong-Sung Kim , Jeong-Hoon Kim , Byoung-Ok Ahn , Moo-Hi Yoo , Mi-Jeong Seo , Ju-Mi Kim , Yong-Duck Kim , Sun-Woo Jang , Yong-Sung Shon
IPC分类号： C07D311/30 , A61K31/352
CPC分类号： C07D311/30 , C07D405/12
摘要： The present invention provides a 3′,4′,5-trimethoxy flavone derivative and a pharmaceutically acceptable salt thereof, preparation thereof, and a pharmaceutical composition for the treatment and prevention of dry eye syndrome comprising the same as an active ingredient.The 3′,4′,5-trimethoxy flavone derivative and its pharmaceutically acceptable salt inhibit corneal damage through excellent stimulatory action on mucus secretion in the conjunctiva and therefore may be effective as a prophylactic or therapeutic agent for dry eye syndrome.
摘要翻译：本发明提供了一种3'，4'，5-三甲氧基黄酮衍生物及其药学上可接受的盐，其制备方法和用于治疗和预防干眼综合征的药物组合物，包括其作为活性成分。 3'，4'，5-三甲氧基黄酮衍生物及其药学上可接受的盐通过对结膜粘液分泌的优异刺激作用而抑制角膜损伤，因此可作为干眼综合征的预防或治疗剂有效。

3. 发明申请

US20110306762A1 ACID ADDITION SALT OF UDENAFIL, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 审中-公开
标题翻译：醋酸加入盐，其制备方法及包含其的药物组合物
公开(公告)号：US20110306762A1
公开(公告)日：2011-12-15
申请号：US13201900
申请日：2010-02-17
申请人： Chan-Ho Lee , Chang-Yong Shin , Seul-Min Choi , Kyung-Koo Kang , Dong-Seong Kim , Byoung-Ok Ahn , Moo-Hi Yoo
发明人： Chan-Ho Lee , Chang-Yong Shin , Seul-Min Choi , Kyung-Koo Kang , Dong-Seong Kim , Byoung-Ok Ahn , Moo-Hi Yoo
IPC分类号： C07D487/04
CPC分类号： C07D487/04
摘要： The present invention provides an acid addition salt of Udenafil, a preparation method thereof and a pharmaceutical composition comprising the same. The acid addition salt of Udenafil in which Udenafil is bonded to an organic acid selected from the group consisting of oxalic acid, benzenesulfonic acid, camphorsulfonic acid, cinnamic acid, adipic acid and cyclamic acid, has excellent solubility in an aqueous medium, water stability and crystallinity, thereby being suitably applied for a pharmaceutical composition.
摘要翻译：本发明提供了Udenafil的酸加成盐，其制备方法和包含其的药物组合物。乌代那芬的酸加成盐，其中，阿登奈芬与选自草酸，苯磺酸，樟脑磺酸，肉桂酸，己二酸和环己烷氨基酸的有机酸结合，在水性介质中具有优异的溶解性，水稳定性和结晶度，从而适合用于药物组合物。

4. 发明授权

US07915302B2 Crystal forms of pyrrolylheptanoic acid derivatives 失效
标题翻译：吡咯并庚酸衍生物的晶体形式
公开(公告)号：US07915302B2
公开(公告)日：2011-03-29
申请号：US12449867
申请日：2008-03-03
申请人： Moon Sung Kim , Moo Hi Yoo , Jae Keol Rhee , Yong Jik Kim , Seong Jin Park , Jun Ho Choi , Si Young Sung , Hong Gyu Lim , Dae Won Cha
发明人： Moon Sung Kim , Moo Hi Yoo , Jae Keol Rhee , Yong Jik Kim , Seong Jin Park , Jun Ho Choi , Si Young Sung , Hong Gyu Lim , Dae Won Cha
IPC分类号： A61K31/40 , C07D207/30
CPC分类号： C07D207/34
摘要： The present invention provides novel crystalline forms D1 and D2 of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemicalcium salt, and hydrates thereof. The crystalline forms D1 and D2 have X-ray powder diffraction peaks described in FIGS. 1 and 3, respectively. Further, the present invention provides processes for preparing the crystalline forms and pharmaceutical compositions comprising the crystalline forms. The crystalline forms can be produced on a commercial scale and exhibit excellent stability.
摘要翻译：本发明提供了[R-（R *，R *）] - 2-（4-氟苯基） - ，β-二羟基-5-（1-甲基乙基）-3-苯基 - 4 - [（苯基氨基）羰基] -1H-吡咯-1-庚酸半钙盐及其水合物。结晶形式D1和D2具有图1和2所述的X射线粉末衍射峰。 1和3。此外，本发明提供了制备结晶形式的方法和包含结晶形式的药物组合物。结晶形式可以以商业规模生产并且表现出优异的稳定性。

5. 发明申请

US20100240725A1 NOVEL 1,3-DIHYDRO-5-ISOBENZOFURANCARBONITRILE DERIVATIVES AND PHARMACEUTICAL COMPOSITION THEREOF FOR THE TREATMENT OF PREMATURE EJACULATION 失效
标题翻译：新型1,3-二氢-5-ISOBENZFURBANITRILE衍生物及其药物组合物，用于治疗预防性呕吐
公开(公告)号：US20100240725A1
公开(公告)日：2010-09-23
申请号：US12739870
申请日：2008-10-31
申请人： Yeong Geon Lee , Soo-Jung Choi , Tae-Kyung Kang , Mi-Jeong Seo , Chang-Yong Shin , Kyung-Seok Lee , Gook-Jun Ahn , Seul-Min Choi , Yong-Duck Kim , Dong-Hwan Kim , Kyung-Koo Kang , Hyun-Joo Shim , Dong-Sung Kim , Byoung-Ok Ahn , Moo-Hi Yoo
发明人： Yeong Geon Lee , Soo-Jung Choi , Tae-Kyung Kang , Mi-Jeong Seo , Chang-Yong Shin , Kyung-Seok Lee , Gook-Jun Ahn , Seul-Min Choi , Yong-Duck Kim , Dong-Hwan Kim , Kyung-Koo Kang , Hyun-Joo Shim , Dong-Sung Kim , Byoung-Ok Ahn , Moo-Hi Yoo
IPC分类号： A61K31/4178 , C07D307/87 , A61K31/343 , A61P15/00 , C07D405/06 , A61K31/4155 , C07D409/04 , A61K31/381
CPC分类号： C07D307/87 , C07D405/06 , C07D409/04 , C07D409/06
摘要： Disclosed herein are novel 1,3-dihydro-5-isobenzofurancarbonitrile derivatives represented by Formula 1, or pharmaceutically acceptable salts thereof. Also disclosed is a pharmaceutical composition for treating or preventing premature ejaculation including the compound. The 1,3-dihydro-5-isobenzofurancarbonitrile derivatives have a short half-life and inhibit the ejaculation process by selectively inhibiting serotonin reuptake via a serotonin reuptake transporter present in a presynaptic neuron. Thus, the compounds are useful in the treatment and prevention of premature ejaculation.
摘要翻译：本文公开了由式1表示的新的1,3-二氢-5-异苯并呋喃腈衍生物或其药学上可接受的盐。还公开了用于治疗或预防早泄的药物组合物，包括该化合物。 1,3-二氢-5-异苯并呋喃腈衍生物具有短的半衰期，并通过选择性地通过存在于突触前神经元中的5-羟色胺再摄取转运蛋白选择性抑制5-羟色胺再摄取来抑制射精过程。因此，这些化合物可用于治疗和预防早泄。

6. 发明申请

US20100173915A1 PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CHRONIC HEART FAILURE COMPRISING PYRAZOLOPYRIMIDINONE DERIVATIVE COMPOUND 审中-公开
标题翻译：用于治疗包含吡唑并吡啶酮衍生化合物的慢性心力衰竭的药物组合物
公开(公告)号：US20100173915A1
公开(公告)日：2010-07-08
申请号：US12602847
申请日：2008-06-03
申请人： Jee-Hyun Shin , Gook-Jun Ahn , Kyung-Koo Kang , Byoung-Ok Ahn , Moo-Hi Yoo
发明人： Jee-Hyun Shin , Gook-Jun Ahn , Kyung-Koo Kang , Byoung-Ok Ahn , Moo-Hi Yoo
IPC分类号： A61K31/519 , A61P9/00 , C07D487/04 , A61P9/04
CPC分类号： A61K31/519 , A61K9/2059 , A61K9/4866
摘要： Disclosed herein is a therapeutic agent for chronic heart failure comprising, as an effective ingredient, 5-[2-propyloxy-5-(1-methyl-2-pyrrolidinyl-ethylamidosulfonyl)phenyl]-1-methyl-propyl-1,6-dihydro-7H-pyrazolo(4,3-d)pyrimidine-7-one. The compound inhibits phosphodiesterase-5 (PDE-5), which catalyzes the intracellular degradation of cyclic guanosine monophosphatase (cGMP), thereby mitigating several signs of chronic heart failure, that is, thereby preventing left ventricular dilatation, decreasing ventricular wall thinning, lowering elevated cardiac and circulating levels of atrial natriuretic peptide (ANP), and inhibiting ventricular fibrosis. Also, the compound has advantages in that it reaches the maximal plasma level in a short time, has an in vivo half-life longer than conventional PDE-5 inhibitors, allowing decreased administration frequency, and has fewer side effects, thus ensuring safety. Thus, the compound is useful as a therapeutic agent for chronic heart failure.
摘要翻译：本文公开了一种用于慢性心力衰竭的治疗剂，其包含作为有效成分的5- [2-丙氧基-5-（1-甲基-2-吡咯烷基 - 乙基氨基磺酰基）苯基] -1-甲基 - 丙基-1,6- 二氢-7H-吡唑并（4,3-d）嘧啶-7-酮。该化合物抑制磷酸二酯酶-5（PDE-5），其催化环鸟苷酸单磷酸酶（cGMP）的细胞内降解，从而减轻慢性心力衰竭的几个迹象，从而预防左心室扩张，降低心室壁变薄，降低升高心脏和循环水平的心房钠尿肽（ANP），并抑制心室纤维化。此外，该化合物具有在短时间内达到最大血浆水平的优点，具有比常规PDE-5抑制剂更长的体内半衰期，允许降低给药频率，并且具有较少的副作用，从而确保安全性。因此，该化合物可用作慢性心力衰竭的治疗剂。

7. 发明申请

US20100130448A1 3',4',5-TRIMETHOXY FLAVONE DERIVATIVES AS STIMULATN OF MUCUS SECRETION, METHOD FOR THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME 有权
标题翻译： 3'，4'，5-三甲基紫杉醇衍生物作为肌肉分泌物的刺激，其方法和包含其的药物组合物
公开(公告)号：US20100130448A1
公开(公告)日：2010-05-27
申请号：US12451902
申请日：2008-06-02
申请人： Seul-Min Choi , Kyung-Koo Kang , Dong-Sung Kim , Jeong-Hoon Kim , Byoung-Ok Ahn , Moo-Hi Yoo , Mi-Jeong Seo , Ju-Mi Kim , Yong-Duck Kim , Sun-Woo Jang , Yong-Sung Shon
发明人： Seul-Min Choi , Kyung-Koo Kang , Dong-Sung Kim , Jeong-Hoon Kim , Byoung-Ok Ahn , Moo-Hi Yoo , Mi-Jeong Seo , Ju-Mi Kim , Yong-Duck Kim , Sun-Woo Jang , Yong-Sung Shon
IPC分类号： A61K31/352 , C07D405/12 , C07D311/76 , C07F9/40 , A61K31/41 , A61K31/665 , A61P27/04
CPC分类号： C07D311/30 , C07D405/12
摘要： The present invention provides a 3′,4′,5-trimethoxy flavone derivative and a pharmaceutically acceptable salt thereof, preparation thereof, and a pharmaceutical composition for the treatment and prevention of dry eye syndrome comprising the same as an active ingredient.The 3′,4′,5-trimethoxy flavone derivative and its pharmaceutically acceptable salt inhibit corneal damage through excellent stimulatory action on mucus secretion in the conjunctiva and therefore may be effective as a prophylactic or therapeutic agent for dry eye syndrome.
摘要翻译：本发明提供了一种3'，4'，5-三甲氧基黄酮衍生物及其药学上可接受的盐，其制备方法和用于治疗和预防干眼综合征的药物组合物，包括其作为活性成分。 3'，4'，5-三甲氧基黄酮衍生物及其药学上可接受的盐通过对结膜粘液分泌的优异刺激作用而抑制角膜损伤，因此可作为干眼综合征的预防或治疗剂有效。

8. 发明申请

US20100113556A1 NOVEL CRYSTAL FORMS OF PYRROLYLHEPTANOIC ACID DERIVATIVES 失效
标题翻译：吡咯烷酮酸衍生物的新型晶体形式
公开(公告)号：US20100113556A1
公开(公告)日：2010-05-06
申请号：US12449867
申请日：2008-03-03
申请人： Moon Sung Kim , Moo Hi Yoo , Jae Keol Rhee , Yong Jik Kim , Seong Jin Park , Jun Ho Choi , Si Young Sung , Hong Gyu Lim , Dae Won Cha
发明人： Moon Sung Kim , Moo Hi Yoo , Jae Keol Rhee , Yong Jik Kim , Seong Jin Park , Jun Ho Choi , Si Young Sung , Hong Gyu Lim , Dae Won Cha
IPC分类号： A61K31/40 , C07D207/30 , A61P3/06
CPC分类号： C07D207/34
摘要： The present invention provides novel crystalline forms D1 and D2 of [R—(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid hemicalcium salt, and hydrates thereof. The crystalline forms D1 and D2 have X-ray powder diffraction peaks described in FIGS. 1 and 3, respectively. Further, the present invention provides processes for preparing the crystalline forms and pharmaceutical compositions comprising the crystalline forms. The crystalline forms can be produced on a commercial scale and exhibit excellent stability.
摘要翻译：本发明提供了[R-（R *，R *）] - 2-（4-氟苯基） - ，β-二羟基-5-（1-甲基乙基）-3-苯基 - 4 - [（苯基氨基）羰基] -1H-吡咯-1-庚酸半钙盐及其水合物。结晶形式D1和D2具有图1和2所述的X射线粉末衍射峰。 1和3。此外，本发明提供了制备结晶形式的方法和包含结晶形式的药物组合物。结晶形式可以以商业规模生产并且表现出优异的稳定性。

9. 发明授权

US08329191B2 Three-branched polyethylene glycol-G-CSF conjugate 有权
标题翻译：三支链聚乙二醇-G-CSF缀合物
公开(公告)号：US08329191B2
公开(公告)日：2012-12-11
申请号：US12515122
申请日：2006-11-22
申请人： Yeong-Woo Jo , Won-Young Yoo , Hyun-Kyu Jeon , Yun-Kyu Choi , Hye-In Jang , Byong-Moon Kim , Sung-Hee Lee , Soo-Hyung Kang , Moo-Hi Yoo
发明人： Yeong-Woo Jo , Won-Young Yoo , Hyun-Kyu Jeon , Yun-Kyu Choi , Hye-In Jang , Byong-Moon Kim , Sung-Hee Lee , Soo-Hyung Kang , Moo-Hi Yoo
IPC分类号： A61K38/00 , C07K14/00 , A61K38/19 , C07K1/00
CPC分类号： A61K9/0019 , A61K31/77 , A61K47/60
摘要： The present invention relates to three-branched PEG-G-CSF conjugate of general formula (1) in which the bonding ratio of three-branched polyethylene glycol (PEG) and G-CSF is 1:1 (mol/mol), wherein PEG has an average molecular weight of from 200 to 45,000 daltons; a pharmaceutical composition comprising the same, and a preparing method thereof.
摘要翻译：本发明涉及三分支PEG-G-CSF缀合物，其中三分支聚乙二醇（PEG）和G-CSF的键合比为1:1（mol / mol），其中PEG 平均分子量为200至45,000道尔顿; 包含其的药物组合物及其制备方法。

10. 发明授权

US08242159B2 1,3-dihydro-5-isobenzofurancarbonitrile derivatives and pharmaceutical composition thereof for the treatment of premature ejaculation 失效
标题翻译： 1,3-二氢-5-异苯并呋喃腈衍生物及其药物组合物，用于治疗早泄
公开(公告)号：US08242159B2
公开(公告)日：2012-08-14
申请号：US12739870
申请日：2008-10-31
申请人： Yeong Geon Lee , Soo-Jung Choi , Tae-Kyung Kang , Mi-Jeong Seo , Chang-Yong Shin , Kyung-Seok Lee , Gook-Jun Ahn , Seul-Min Choi , Yong-Duck Kim , Dong-Hwan Kim , Kyung-Koo Kang , Hyun-Joo Shim , Dong-Sung Kim , Byoung-Ok Ahn , Moo-Hi Yoo
发明人： Yeong Geon Lee , Soo-Jung Choi , Tae-Kyung Kang , Mi-Jeong Seo , Chang-Yong Shin , Kyung-Seok Lee , Gook-Jun Ahn , Seul-Min Choi , Yong-Duck Kim , Dong-Hwan Kim , Kyung-Koo Kang , Hyun-Joo Shim , Dong-Sung Kim , Byoung-Ok Ahn , Moo-Hi Yoo
IPC分类号： A61K31/415 , A61K31/4164 , A61K31/38 , A61K31/34 , C07D233/00 , C07D231/00 , C07D409/00 , C07D307/02
CPC分类号： C07D307/87 , C07D405/06 , C07D409/04 , C07D409/06
摘要： Disclosed herein are novel 1,3-dihydro-5-isobenzofurancarbonitrile derivatives represented by Formula 1, or pharmaceutically acceptable salts thereof. Also disclosed is a pharmaceutical composition for treating or preventing premature ejaculation including the compound. The 1,3-dihydro-5-isobenzofurancarbonitrile derivatives have a short half-life and inhibit the ejaculation process by selectively inhibiting serotonin reuptake via a serotonin reuptake transporter present in a presynaptic neuron. Thus, the compounds are useful in the treatment and prevention of premature ejaculation.
摘要翻译：本文公开了由式1表示的新的1,3-二氢-5-异苯并呋喃腈衍生物或其药学上可接受的盐。还公开了用于治疗或预防早泄的药物组合物，包括该化合物。 1,3-二氢-5-异苯并呋喃腈衍生物具有短的半衰期，并通过选择性地通过存在于突触前神经元中的5-羟色胺再摄取转运蛋白选择性抑制5-羟色胺再摄取来抑制射精过程。因此，这些化合物可用于治疗和预防早泄。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式